Can radium-223 be given to prostate cancer patients with a history of visceral metastatic disease?
Can radium-223 be given to patients with progressive diffuse osseous mets if they have a history of visceral mets that resolved with previous treatment? ALYSMPCA excluded these patients, but is a history of visceral mets a contraindication?
1 Answer
Mednet Member
Radiation Oncology · Mayo Clinic Arizona
Answered on
Radium-223 is a bone-targeted radiopharmaceutical. In the ALSYMPCA trial, patients with visceral metastases or lymphadenopathy>3cm were excluded. However, if a patient with mCRPC has visceral disease that resolved with previous treatment, and now has progressive osseous metastases, it would be very ...
Join for free or sign in to see the full answer